Navigation Links
Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting

TAMPA, Fla., April 23, 2007 /PRNewswire/ -- Sirion Therapeutics announced today that data on two of the Company's pipeline compounds, ST-601 (difluprednate) and ST-602 (fenretinide), will be presented at the 2007 annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) in Ft. Lauderdale, FL. In addition to these presentations, the company will be hosting a reception for ARVO attendees.

ST-601 (difluprednate) is currently being evaluated in two phase III clinical trials in the treatment of ocular inflammation following cataract surgery. ST-601 (difluprednate) was acquired by Sirion last year through an exclusive licensing agreement with Senju Pharmaceutical Co., LTD of Japan. The agreement gives Sirion the U.S. rights to develop and market a topical ophthalmic emulsion containing the steroid compound difluprednate for the treatment of inflammatory eye diseases and conditions.

ST-602 (fenretinide) is currently being evaluated in a phase II clinical trial in the treatment of Geographic Atrophy (GA) in patients with age-related macular degeneration. The trial is a multicenter, randomized, double-masked, placebo controlled, dose-comparison in up to 225 patients in approximately 20 sites in the United States.

"We are pleased to announce the upcoming schedule of presentations relating to difluprednate and fenretinide at the ARVO annual conference. ARVO is the one of the oldest, largest and most highly respected vision research organizations in the world," stated Barry Butler, President and Chief Executive Officer of Sirion Therapeutics. "This is exciting news for our company in that it is the first time we will be presenting scientific data on our pipeline compounds. These presentations will provide support of the potential future clinical utility of these compounds in the treatment of ophthalmic eye diseases and conditions and demonstrate our commitment to discovering, de
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the United States Patent and Trademark Office ("USPTO") ... things, purified collagenase, the active component in Auxilium,s ... "COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES" is ...
... Ocular Therapeutix, Inc. announced today the completion ... with their novel sustained drug delivery moxifloxacin punctum ... single-armed, single-dose study in which ten patients received ... were evaluated over a 10-day period. Primary outcome ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 2Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 3Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase 4Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs 2Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs 3
(Date:1/22/2015)... Glendale, AZ (PRWEB) January 22, 2015 Padre ... a long supporter of Pro Player Health Alliance ... with Padre Murphy's in getting everyone, including NFL greats, treated ... one of the leading groups supporting the cause in the ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Walk this way and a camera-carrying robot will follow. That ... Fortunately, Steven Irby, an engineer in the Motion Analysis Lab ... to look for someone who could handle those details. ... routinely tackle such challenges for their senior design projects. In ...
... ... , ... (Vocus) May 5, 2010 -- Blue Cross Blue Shield of Massachusetts (BCBSMA), ... C. Van Faasen Community Service Sabbatical. BCBSMA’s sabbatical program gives one employee per year ...
... Men tend to be treated for alcohol misuse, women ... (HealthDay News) -- Mexican-American women and men have marked ... U.S. study. , Researchers analyzed 2007 data from substance ... substance of abuse among male Mexican Americans admitted for ...
... ... your Mother a spa for Mother,s Day this weekend at Market Hall in Dallas. Your Mother and ... just outside the back door... , ... 5, 2010 -- Give her a gift that will last a lifetime. “A high end Spa or ...
... ... combating global poverty as part of the Millennium Development Goals , ... Washington, DC (Vocus) May 5, 2010 — New public ... The data released today by the United Nations Foundation and its sister organization ...
... of combined positron emission tomography and computed tomography (PET/CT) ... early stage, helping significantly in treatment planning and improved ... presented at the ARRS 2010 Annual Meeting in San ... imaging that uses traces of radioactive material to diagnose ...
Cached Medicine News:Health News:Rice team talks the walk 2Health News:Rice team talks the walk 3Health News:Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical 2Health News:Blue Cross Blue Shield of Massachusetts Demonstrates Community Commitment with Fifth William C. Van Faasen Community Service Sabbatical 3Health News:Substance Abuse in Mexican Americans Differs by Gender 2Health News:Buy Ma a Spa for Mothers Day This Weekend at Market Hall in Dallas at the Spa, Pool and Sauna Show 2Health News:United Nations Approval Rating rises to 60% in New Opinion Poll 2Health News:United Nations Approval Rating rises to 60% in New Opinion Poll 3Health News:United Nations Approval Rating rises to 60% in New Opinion Poll 4
... a complete line of ... halogen light sources that ... A solid-state dimmer provides ... our exclusive Modulamp assembly ...
Inquire...
... inverted microscope technology that offers you much more ... in this category. You will be impressed by ... been designed to make lab work as easy ... efficiency of your workflow. Your advantage: more time ...
... IX81 represents the most advanced motorized inverted ... frame and optical design provides 9 access ... Up to four ports can have simultaneous ... built-in motorized Z-axis drive, 6-position nosepiece and ...
Medicine Products: